Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Sponsor
Xinxin Zhang
Study ID
NCT06932861
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Rhabdomyosarcoma

Eligibility Criteria

Sex
ALL
Age
6 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • mRNA Tumor Vaccine Therapy — BIOLOGICAL
    personalized mRNA vaccines

Study Details

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Key Dates

First listed
Apr 17, 2025
Start date
May 1, 2025
Status verified
Apr 2025
Primary completion
May 1, 2027
Completion
May 1, 2028

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vaccine arm

Primary Outcome Measure

Adverse Event [ Time Frame: From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first. ]

Central Contacts

Related Studies